|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li S, Choi YL, Gong Z, Liu X, Lira M, Kan
Z, Oh E, Wang J, Ting JC, Ye X, et al: Comprehensive
characterization of oncogenic drivers in asian lung adenocarcinoma.
J Thorac Oncol. 11:2129–2140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mantovani A, Romero P, Palucka AK and
Marincola FM: Tumour immunity: Effector response to tumour and role
of the microenvironment. Lancet. 371:771–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Solan MJ and Werner-Wasik M: Prognostic
factors in non-small cell lung cancer. Semin Surg Oncol. 21:64–73.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrara N: The role of VEGF in the
regulation of physiological and pathological angiogenesis. Exs. pp.
209–231. 2005
|
|
10
|
Mattern J, Koomagi R and Volm M:
Association of vascular endothelial growth factor expression with
intratumoral microvessel density and tumour cell proliferation in
human epidermoid lung carcinoma. Br J Cancer. 73:931–934. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lohela M, Bry M, Tammela T and Alitalo K:
VEGFs and receptors involved in angiogenesis versus
lymphangiogenesis. Curr Opin Cell Biol. 21:154–165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coultas L, Chawengsaksophak K and Rossant
J: Endothelial cells and VEGF in vascular development. Nature.
438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibuya M: Differential roles of vascular
endothelial growth factor receptor-1 and receptor-2 in
angiogenesis. J Biochem Mol Biol. 39:469–478. 2006.PubMed/NCBI
|
|
16
|
Zhang Z, Neiva KG, Lingen MW, Ellis LM and
Nor JE: VEGF-dependent tumor angiogenesis requires inverse and
reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ.
17:499–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kowanetz M and Ferrara N: Vascular
endothelial growth factor signaling pathways: Therapeutic
perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chansky K, Sculier JP, Crowley JJ, Giroux
D, van Meerbeeck J and Goldstraw P; International Staging Committee
and Participating Institutions: The International Association for
the study of lung cancer staging project. Prognostic factors and
pathologic TNM stage in surgically managed non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 4:792–801. 2009.(In Chinese).
|
|
20
|
Chen P, Zhu J, Liu DY, Li HY, Xu N and Hou
M: Over-expression of survivin and VEGF in small-cell lung cancer
may predict the poorer prognosis. Med Oncol. 31:7752014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holzer TR, Fulford AD, Reising LO,
Nedderman DM, Zhang X, Benjamin LE, Schade AE and Nasir A:
Profiling of vascular endothelial growth factor receptor
heterogeneity identifies protein expression-defined subclasses of
human non-small cell lung carcinoma. Anticancer Res. 36:3277–3288.
2016.PubMed/NCBI
|
|
22
|
de Mello RA, Madureira P, Carvalho LS,
Araújo A, O Brien M and Popat S: EGFR and KRAS mutation, and ALK
fusioin: current developments and personalized therapies for
patients with advanced non-small-cell ling cancer.
Pharmacogenomics. 14:1765–1777. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
E J, Xing J, Gong H, He J and Zhang W:
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory
tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due
to reduced expression of VEGF and matrix metallopeptidase-9. Tumour
Biol. 36:1091–1097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirai H, Sootome H, Nakatsuru Y, Miyama K,
Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and
Kotani H: MK-2206, an allosteric Akt inhibitor, enhances antitumor
efficacy by standard chemotherapeutic agents or molecular targeted
drugs in vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engelman JA, Chen L, Tan X, Crosby K,
Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y,
et al: Effective use of PI3K and MEK inhibitors to treat mutant
Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med.
14:1351–1356. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng J, Dai B, Fang B, Bekele BN, Bornmann
WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, et
al: Combination treatment with MEK and AKT inhibitors is more
effective than each drug alone in human non-small cell lung cancer
in vitro and in vivo. PLoS One. 5:e141242010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corcoran RB, Cheng KA, Hata AN, Faber AC,
Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et
al: Synthetic lethal interaction of combined BCL-XL and MEK
inhibition promotes tumor regressions in KRAS mutant cancer models.
Cancer Cell. 23:121–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Mello RA, Marques DS, Medeiros R and
Araujo AM: Epidermal growth factor receptor and K-Ras in non-small
cell lung cancer-molecular pathways involved and targeted
therapies. World J Clin Oncol. 2:367–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reinmuth N, Jauch A, Xu EC, Muley T,
Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth
FJ, et al: Correlation of EGFR mutations with chromosomal
alterations and expression of EGFR, ErbB3 and VEGF in tumor samples
of lung adenocarcinoma patients. Lung Cancer. 62:193–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Clarke K, Smith K, Gullick WJ and Harris
AL: Mutant epidermal growth factor receptor enhances induction of
vascular endothelial growth factor by hypoxia and insulin-like
growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer.
84:1322–1329. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, Ren Z, Wang J and Zhang S:
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy
is especially beneficial to patients with exon 19 deletion compared
with exon 21 L858R mutation in non-small-cell lung cancer:
Systematic review and meta analysis. Thorac Cancer. 7:406–414.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schimanski CC, Zimmermann T, Schmidtmann
I, Gockel I, Lang H, Galle PR, Moehler M and Berger MR: K-ras
mutation status correlates with the expression of VEGFR1, VEGFR2,
and PDGFRalpha in colorectal cancer. Int J Colorectal Dis.
25:181–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mancikova V, Inglada-Pérez L,
Curras-Freixes M, de Cubas AA, Gómez Á, Letón R, Kersten I,
Leandro-García LJ, Comino-Méndez I, Apellaniz-Ruiz M, et al: VEGF,
VEGFR3, and PDGFRB protein expression is influenced by RAS
mutations in medullary thyroid carcinoma. Thyroid. 24:1251–1255.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krajnović M, Marković B, Knežević-Ušaj S,
Nikolić I, Stanojević M, Nikolić V, Šiljić M, Jovanović Ćupić S and
Dimitrijević B: Locally advanced rectal cancers with simultaneous
occurrence of KRAS mutation and high VEGF expression show invasive
characteristics. Pathol Res Pract. 212:598–603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang YH, Kim KS, Yu YK, Lim SC, Kim YC and
Park KO: The relationship between microvessel count and the
expression of vascular endothelial growth factor, p53, and K-ras in
non-small cell lung cancer. J Korean Med Sci. 16:417–423. 2001.
View Article : Google Scholar : PubMed/NCBI
|
